Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
Shigeki Nanjo(Kanazawa University), Seiji Yano(Kanazawa University)
Cited by 44
Related Papers
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
|Nature Communications|2019|360
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
|Nature Communications|2020|112
Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in <i>EGFR</i> -T790M Mutant Lung Cancer
|Clinical Cancer Research|2009|97